With the seven pharmerging markets all set to change the landscape of the pharmaceutical industry globally, the Indian pharma companies would do well to rediscover and reposition themselves to tap the opportunities.

The Indian pharmaceutical industry has continued to witness a robust 12-14% growth in recent years, against the global pharmaceutical industry growth of just 6% a year. According to Market Intelligence Report June 2009, the world is closely looking at seven key markets—Brazil, Russia, India, China, Turkey, South Korea and Mexico—for future growth. These markets can also be called the `pharmerging markets', as these markets have the potential to drive the growth of the global pharmaceutical industry. The pharmerging market conglomerate is expected to almost double in size by 2013 to match the size of Europe, with an expected CAGR of 13-16%. Rising GDP, a transitional disease profile, growing access to better medical care, better healthcare delivery and expanding public health awareness, will remain key drivers.

The pharmaceutical market in India is estimated to be around $10 bn, growing approximately 9% annually. In world ranking, the domestic pharma industry stands 4^th in terms of volume and 13^th in terms of value. All in all, India is poised for significant growth and remarkable visibility in global healthcare contribution.

The Analyst Magazine, Market conglomerate, Gross Domestic Product, GDP, Mergers and acquisitions, M&As, Global Pharmaceutical Industry, Global Healthcare Contribution, Contract Research & Manufacturing Services, CRAMS, Market Intelligence Report.